Here’s what you should know:
1. Although Bekinda did meet its primary endpoint of improved stool consistency, it did not meet its secondary endpoints of improved abdominal pain or improved overall response in patients.
2. Shares of RedHill closed at $10.81 Oct. 2. They fell to $9.03 Oct. 3, before closing at $9.39 later in the day.
3. RedHill’s Chief Executive Dror Ben-Asher told Reuters, the study wasn’t designed to show significance in the secondary endpoints. He said, “The results are actually good according to the small sample size.”
4. RedHill anticipates beginning a late-stage trial on Bekinda by late 2018.
More articles on gastroenterology:
GI leader to know: Dr. Steven Desautels of Granite Peaks Gastroenterology
Stock market week-in-review for 5 large GI companies — Sept. 25-29
Drug designations, new devices & more — 15 GI company key notes for September
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
